Rapid Resolution of Suicidal Ideation After a Single Infusion of an N -Methyl- D -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD). Method Thirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009. Results Suicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P Conclusions Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health. Trial registration clinicaltrials.gov Identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [38]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [131]
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [151]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [7]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Linehan, M. M., Comtois, K. A., Murray, A. M., Brown, M. Z., Gallop, R. J., Heard, H. L., Korslund, K. E., Tutek, D. A., Reynolds, S. K., & Lindenboim, N. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.757 · Cited by 2,025
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Cognitive Therapy for the Prevention of Suicide Attempts: A Randomized Controlled Trial
Brown, G. K., Ten Have, T., Henriques, G. R., Xie, S. X., Hollander, J. E., & Beck, A. T. (2005) · JAMA · doi:10.1001/jama.294.5.563 · Cited by 1,045
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Cited by
Items 101–200 of 570
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Self-citationThe role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 138
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
Self-citationReview of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 146
“Intravenous drug delivery, although less useful in an out-patient setting, could be beneficial for hospitalized depressed patients who require rapid response to treatment, and for emergency management of suicidality in depressed patients, a condition that has shown response to ketamine infusion (”
BackgroundQu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16060-7 · Cited by 127
Sit, D., Luther, J., Buysse, D., Dills, J. L., Eng, H., Okun, M., Wisniewski, S., & Wisner, K. L. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.021 · Cited by 121
“For treatment-resistant disorders, medication options which can reduce suicidal symptoms include lithium (Goodwin et al., 2003; Tondo et al., 2001), clozapine (Meltzer and Okayli, 1995; Potkin et al., 2003) and possibly, ketamine (DiazGranados et al., 2010).”
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
“Ketamine may have a specific and unique role in acute suicidality in an emergency room setting and as an anesthetic prior to ECT therapy, where trials are currently under way to investigate ketamine’s efficacy [23,49,50].”
BackgroundTransient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123
Bobo, W. V., Vande Voort, J. L., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 123
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Inflammatory Factors Contribute to Depression and Its Comorbid Conditions
Anisman, H., & Hayley, S. (2012) · Science Signaling · doi:10.1126/scisignal.2003579 · Cited by 117
“Administration of the NMDA receptor antagonist ketamine even to treatment-resistant and suicidal patients has produced an immediate antidepressant response (23).”
BackgroundKetamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120
“Notably, only three studies have directly examined SI as the primary outcome [11, 16, 17], while the rest examined SI as the secondary outcome [4, 15, 18], not including case reports.”
BackgroundOrozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.1176 · Cited by 119
Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Rothenhäusler, H., Theokas, S., Robier, C., Mangge, H., Reicht, G., Hlade, P., & Meinitzer, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160542 · Cited by 127
“[25] reported that a single infusion of ketamine decreased suicidal ideation scores in treatment-resistant patients with major depression disorder within 40 minutes.”
BackgroundBenedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., & Colombo, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08455 · Cited by 116
Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis
Bartoli, F., Riboldi, I., Crocamo, C., Brita, C. D., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.010 · Cited by 121
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 106
“Further evidence showed that ketamine is also effective in treating major depressive episodes of treatment-resistant bipolar disorder [5,6], rapidly decreasing suicidal ideation [7,8] and reducing anhedonia [9].”
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., & Pariante, C. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.87 · Cited by 108
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 106
“…L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., Machado-Vieira, R., Manji, H. K., and Zarate, C. A., Jr. (2010) A randomized add-on trial of an Nmethyl-D-aspartate antagonist in treatment-resistant bipolar depression.”
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2015) · Bipolar Disorders · doi:10.1111/bdi.12277 · Cited by 104
“Indeed, ketamine has been shown to rapidly and robustly reduce symptoms of depression in a sample of patients with treatment-resistant bipolar disorder (with and without anxiety) (13, 14).”
Self-citationSchwieler, L., Samuelsson, M., Frye, M. A., Bhat, M., Schuppe-Koistinen, I., Jungholm, O., Johansson, A. G., Landén, M., Sellgren, C. M., & Erhardt, S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0517-7 · Cited by 106
“Interestingly, ketamine, an NMDA-receptor antagonist, has also been reported to exert a rapid antidepressant effect in patients with depression [48 – 50].”
BackgroundFaster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“These preclinical findings have been significantly bolstered by relatively recent clinical studies demonstrating that a single sub-anaesthetic dose of the NMDA receptor antagonist, ketamine, has antidepressant effects and reduces suicidal ideation (Aan Het Rot et al., 2012; Berman et al., 2000; DiazGranados et al., 20…”
BackgroundResultZhao, J., Verwer, R. W. H., Gao, S.-F., Qi, X.-R., Lucassen, P. J., Kessels, H. W., & Swaab, D. F. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.04.020 · Cited by 102
“…ketamine decreased suicidal ideation with treatment-resistant depression within 40 min, and these decreases remained signi fi cant through the fi rst 4 h post-infusion which appears that one of the earliest e ff ects of the drug is a profound reduction in suicidal thoughts (DiazGranados et al., 2010).”
BackgroundThe role of adipokines in the rapid antidepressant effects of ketamine
Machado-Vieira, R., Gold, P. W., Luckenbaugh, D. A., Ballard, E. D., Richards, E. M., Henter, I. D., De Sousa, R. T., Niciu, M. J., Yuan, P., & Zarate, C. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.36 · Cited by 102
Self-citationCui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 108
Myung, W., Han, C. E., Fava, M., Mischoulon, D., Papakostas, G. I., Heo, J.-Y., Kim, K. W., Kim, S. T., Kim, D. J. H., Kim, D. K., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.110 · Cited by 101
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 98
Self-citationExisting and Novel Biological Therapeutics in Suicide Prevention
Griffiths, J. J., Zarate, C. A., & Rasimas, J. J. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.06.012 · Cited by 93
Self-citationGlutamatergic Modulators in Depression
Henter, I. D., de Sousa, R. T., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 92
Self-citationPerspectives for therapy of treatment‐resistant depression
Papp, M., Cubała, W. J., Święcicki, Ł., Newman‐Tancredi, A., & Willner, P. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15596 · Cited by 104
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 90
Robson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 110
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 92
“Ketamine targets NMDARmediated signalling, increases synaptogenesis, and its therapeutic effects are probably mediated by signals downstream of glutamatergic neurotransmission (DiazGranados et al. 2010b ; Li et al. 2010; Sanacora et al. 2008).”
BackgroundMethodInfluentialSelf-citationNeuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
“…found not only to promote fast-acting (within hours) antidepressant and anti-suicidal effects but also to be effective in heretofore treatment-resistant patients (Berman et al., 2000; Zarate et al., 2006; Liebrenz et al., 2007; Price et al., 2009; DiazGranados et al., 2010; Ibrahim et al., 2011).”
BackgroundNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“Ketamine was also found to have significant antisuicidal effects (Diazgranados et al., 2010b, Price et al., 2009).”
BackgroundSelf-citationHydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000149 · Cited by 92
“…receptor; p4E-BP1, phosphorylated eukaryotic initiation factor 4E binding protein 1; pERK, phosphorylated extracellular signal–related kinase; TrkB, tropomyosin receptor kinase B. weeks) [e.g., Berman et al. (2000); Zarate et al. (2006); DiazGranados et al. (2010); Price et al. (2014)].”
BackgroundSelf-citationKetamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 98
“In bipolar depression peak reduction in mood rating scales was noted as early as 40 minutes after start of infusion (Diazgranados et al., 2010a; Zarate et al., 2012b).”
BackgroundMethodResultInfluentialAcute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 86
Sun, Y., Blumberger, D. M., Mulsant, B. H., Rajji, T. K., Fitzgerald, P. B., Barr, M. S., Downar, J., Wong, W., Farzan, F., & Daskalakis, Z. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0302-8 · Cited by 85
Moaddel, R., Shardell, M., Khadeer, M., Lovett, J., Kadriu, B., Ravichandran, S., Morris, P. J., Yuan, P., Thomas, C. J., Gould, T. D., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4992-7 · Cited by 81
Self-citationStratinaki, M., Varidaki, A., Mitsi, V., Ghose, S., Magida, J., Dias, C., Russo, S. J., Vialou, V., Caldarone, B. J., Tamminga, C. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214696110 · Cited by 81
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
Domany, Y., Shelton, R. C., & McCullumsmith, C. B. (2020) · Depression and Anxiety · doi:10.1002/da.22975 · Cited by 84
Bettio, L. E. B., Cunha, M. P., Budni, J., Pazini, F. L., Oliveira‐Giacomelli, Á., Colla, A. R. D. S., & Rodrigues, A. L. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.021 · Cited by 89
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 96
“Moreover, studies have shown a rapid and robust antidepressant action of ketamine in treatment-resistant depressed patients and determined that suicidal ideation was significantly reduced (Price et al., 2009, DiazGranados et al., 2010).”
BackgroundAnimal models to improve our understanding and treatment of suicidal behavior
Gould, T. D., Georgiou, P., Brenner, L. A., Brundin, L., Can, A., Courtet, P., Donaldson, Z. R., Dwivedi, Y., Guillaume, S., Gottesman, I. I., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.50 · Cited by 80
Self-citationHeart and soul: heart rate variability and major depression
Kidwell, M., & Ellenbroek, B. A. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000387 · Cited by 86
“To examine this, DiazGranados et al. (2010) treated suicidal patients with a single intravenous infusion of ketamine.”
Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
López-Gil, X., Jiménez-Sánchez, L., Campa, L., Castro, E., Frago, C., & Adell, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00288 · Cited by 80
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
Ballard, E. D., Luckenbaugh, D. A., Richards, E. M., Walls, T. L., Brutsché, N. E., Ameli, R., Niciu, M. J., Vande Voort, J. L., & Zarate, C. A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.003 · Cited by 80
“…efficacy of ketamine in the treatment of depression (both treatment-resistant major depressive disorder (MDD) and bipolar I or II (BD) depression); results of these studies have been published elsewhere (Diazgranados et al., 2010b; Ibrahim et al., 2012; Zarate et al., 2012; Zarate et al., 2006).”
Self-citationiPlasticity: Induced juvenile‐like plasticity in the adult brain as a mechanism of antidepressants
Umemori, J., Winkel, F., Didio, G., Llach Pou, M., & Castrén, E. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12683 · Cited by 80
“Moreover, administration of ketamine also decreases suicidal ideation in treatment-resistant depressed patients.(64,66,67) One feature of ketamine is its fast-acting production of AD effects, which can already be observed within 4 h after a single administration,(68) whereas other conventional AD take several weeks to…”
BackgroundRapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
Sutterland, A. L., Kuin, A., Kuiper, B., van Gool, T., Leboyer, M., Fond, G. B., & de Haan, L. (2019) · Psychological Medicine · doi:10.1017/s0033291719000813 · Cited by 85
Noradrenergic Dysfunction in Depression and Suicide
Chandley, M., & Ordway, G. (2012) · Frontiers in Neuroscience · doi:10.1201/b12215-4 · Cited by 72
Zurek, A. A., Bridgwater, E. M., & Orser, B. A. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31824720da · Cited by 94
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Vanle, B., Olcott, W., Jimenez, J., Bashmi, L., Danovitch, I., & IsHak, W. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0162-2 · Cited by 73
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Kalmoe, M. C., Janski, A. M., Zorumski, C. F., Nagele, P., Palanca, B. J., & Conway, C. R. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116778 · Cited by 74
Neural Correlates of Suicidal Ideation and Its Reduction in Depression
Ballard, E. D., Lally, N., Nugent, A. C., Furey, M. L., Luckenbaugh, D. A., & Zarate, C. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu069 · Cited by 73
“Ketamine, an N-methyl-d-aspartate receptor antagonist, has demonstrated efficacy in rapidly decreasing both depression and suicidal thoughts within hours after intravenous infusion (DiazGranados et al., 2010; Price et al., 2014).”
BackgroundSelf-citationBallard, E. D., Yarrington, J. S., Farmer, C. A., Lener, M. S., Kadriu, B., Lally, N., Williams, D., Machado-Vieira, R., Niciu, M. J., Park, L., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.027 · Cited by 74
“Details regarding study designs can be found elsewhere (Diazgranados et al., 2010b; Ibrahim et al., 2012; Zarate et al., 2012, 2006).”
BackgroundSelf-citationVisentin, A. P. V., Colombo, R., Scotton, E., Fracasso, D. S., Rosa, A. R., Branco, C. S., & Salvador, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2972968 · Cited by 88
“In two case-control studies, ketamine had an antisuicidal effect in the TRD subjects [111, 112].”
BackgroundGray colored glasses: Is major depression partially a sensory perceptual disorder?
Fitzgerald, P. J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.045 · Cited by 82
“Acute infusion of ketamine to persons with major depression also produces rapid improvements in suicidal ideation (DiazGranados et al., 2010).”
BackgroundPennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.026 · Cited by 77
“Two papers reported the results of a double-blind, placebo-controlled study of a single subanesthetic dose of ketamine in current bipolar depression (“ketamine bipolar”; NCT#00088699, NIH Protocol #04-M-0222, substudy 2) (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundResultInfluentialSelf-citationA New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
“At subanesthetic doses, ketamine is a rapid-onset, efficacious antidepressant capable of mitigating depressive symptoms and measures of suicidality in treatment-resistant mood disorders.(16,18,19) Replicated evidence suggests that a single 0.”
BackgroundGulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies
Dickey, B., Madhu, L. N., & Shetty, A. K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107716 · Cited by 73
“Ketamine, an FDA-approved drug for treatment-resistant depression (Kaufman, 2019), is effective in patients with major depression and suicidal ideation (DiazGranados et al., 2010).”
BackgroundTreccani, G., Ardalan, M., Chen, F., Musazzi, L., Popoli, M., Wegener, G., Nyengaard, J. R., & Müller, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1613-3 · Cited by 73
Kadriu, B., Gold, P. W., Luckenbaugh, D. A., Lener, M. S., Ballard, E. D., Niciu, M. J., Henter, I. D., Park, L. T., De Sousa, R. T., Yuan, P., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.109 · Cited by 70
“Data were drawn from previous studies exploring ketamine’s mechanism of action (NCT00088699); results of these studies have been previously published (44, 45).”
Self-citationZhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M., & Ning, Y. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798614 · Cited by 73
“…decades, ketamine has demonstrated rapid-onset antidepressant effects in patients with treatment-resistant depression (TRD) (Berman et al., 2000; Diazgranados et al., 2010a; Murrough et al., 2013a; Zarate et al., 2006) and rapid reductions in suicidal cognition in patients with suicidal…”
BackgroundMethodInfluentialBari, A. A., Mikell, C. B., Abosch, A., Ben-Haim, S., Buchanan, R. J., Burton, A. W., Carcieri, S., Cosgrove, G. R., D’Haese, P.-F., Daskalakis, Z. J., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317082 · Cited by 71
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 80
Nikkheslat, N. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 71
Machado-Vieira, R., Soeiro-De-Souza, M. G., Richards, E. M., Teixeira, A. L., & Zarate, C. A. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.830775 · Cited by 69
“…addition, two double-blind, placebo-controlled ketamine studies have been conducted in individuals with bipolar depression; both found that ketamine had rapid and sustained antidepressant effects, as well as antisuicidal effects, in bipolar depression (DiazGranados et al. 2010; Zarate et al. 2012).”
Self-citationOnaolapo, A. Y., & Onaolapo, O. J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.297 · Cited by 81
Burger, J., Capobianco, M., Lovern, R., Boche, B., Ross, E., Darracq, M. A., & McLay, R. (2016) · Military Medicine · doi:10.7205/milmed-d-15-00431 · Cited by 67
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 69
Thomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Ketamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 72
Manosso, L. M., Neis, V. B., Moretti, M., Daufenbach, J. F., Freitas, A. E., Colla, A. R., & Rodrigues, A. L. S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.012 · Cited by 68
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Koike, H., Iijima, M., & Chaki, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.017 · Cited by 75
Chiu, C.-T., Scheuing, L., Liu, G., Liao, H.-M., Linares, G. R., Lin, D., & Chuang, D.-M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu102 · Cited by 66
“Recent clinical and preclinical research indicates that, in treatment-resistant MDD and BD subjects, a single subanesthetic dose of ketamine not only produces a rapid antidepressant effect within hours of administration, but also improves suicidal ideation (Berman et al., 2000; Zarate et al., 2006; DiazGranados et al.…”
BackgroundZhang, M. W., Harris, K. M., & Ho, R. C. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0087-3 · Cited by 65
“Previous studies reported dissociative and psychotomimetic effects after ketamine infusions, explained above [35].”
BackgroundAn update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
“Aan Het Rot et al. [93] demonstrated the positive effects of repeated dosing of ketamine infusions (six infusions 0.5mg/kg over 12 days) in medication-free symptomatic patients with TRD who had previously shown an antidepressant response to a single dose.”
BackgroundInfluentialRiggs, L. M., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E. X., Pereira, E. F. R., Thompson, S. M., & Gould, T. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0443-3 · Cited by 66
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 71
The role of serotonin in depression—A historical roundup and future directions
Bremshey, S., Groß, J., Renken, K., & Masseck, O. A. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16097 · Cited by 71
“In clinical trials treatment with low doses of intravenous ketamine resulted in a significant reduction in symptoms within hours (Berman et al., 2000; DiazGranados et al., 2010; Zarate et al., 2006).”
Vande Voort, J. L., Ballard, E. D., Luckenbaugh, D. A., Bernert, R. A., Richards, E. M., Niciu, M. J., Park, L. T., Machado-Vieira, R., Duncan, W. C., & Zarate, C. A. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10440 · Cited by 65
Self-citationNeurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder
Zheng, W., Zhou, Y.-L., Liu, W.-J., Wang, C.-Y., Zhan, Y.-N., Li, H.-Q., Chen, L.-J., Li, M.-D., & Ning, Y.-P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.005 · Cited by 64
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Self-citationMarsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 73
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Pocivavsek, A., Schwarcz, R. M., & Erhardt, S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000239 · Cited by 75
Role of astrocytes in memory and psychiatric disorders
Moraga‐Amaro, R., Jerez-Baraona, J. M., Simón, F., & Stehberg, J. (2014) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2014.08.005 · Cited by 74
“5 mg/kg) intravenous infusions of the NMDA antagonist ketamine, induces rapid antidepressant effects in patients with MD and bipolar depression (DiazGranados et al., 2010; Zarate et al., 2006).”
BackgroundInfluentialKetamine for depression: evidence, challenges and promise
Zarate, C. A., & Niciu, M. J. (2015) · World Psychiatry · doi:10.1002/wps.20269 · Cited by 61
“in patients with treatment-resistant major depressive disorder and bipolar depression (2-7).”
BackgroundSelf-citationStrong, C. E., & Kabbaj, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.09.001 · Cited by 60
“However, following acute ketamine treatment, most patients remitted (DiazGranados et al., 2010; Zarate et al., 2006), suggesting a need for repeated infusions to maintain long-term therapeutic efficacy.”
BackgroundInfluentialHighland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
“(R,S)-ketamine (ketamine) has gained attention for its rapid antidepressant actions in human clinical trials (Berman et al., 2000; DiazGranados et al., 2010; Price et al., 2014; Zarate et al., 2006).”
Self-citationBanov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 66
“…1, 2, 3, 7, 10, and 14 days post-infusion Depression and anxiety symptoms across various outcome measures improved as early as 40min post-infusion Diazgranados et al. (2010) Randomized, placebocontrolled, double-blind, crossover trial Treatment-resistant bipolar disorder 18 Single dose of 0.5…”
BackgroundInfluentialMolecular Neurobiology and Promising New Treatment in Depression
Jeon, S. R., & Kim, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030381 · Cited by 73
“A ketamine injection in treatment-resistant patients with depression induced very rapid antidepressant effects [95].”
BackgroundIglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J. M., & Irwin, S. A. (2015) · Psychosomatics · doi:10.1016/j.psym.2014.05.005 · Cited by 60
Metadata
- Authors
- DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A.
- Affiliations
- National Institute of Mental Health (US)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-07-13
- Volume
- 71
- Issue
- 12
- Pages
- 1605-1611
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3012738
- OpenAlex
- W2103255996
- Cited by
- 564
- References
- 41
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 41 · 2021: 41 · 2020: 39 · 2019: 35 · 2018: 49 · 2017: 33 · 2016: 51 · 2015: 59 · 2014: 52 · 2013: 40 · 2012: 30
- FWCI
- 23.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 MH999999)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- suicidal ideation, ketamine, NMDA receptor antagonists, rapid antidepressant effects, single-dose infusion, hopelessness, anxiety, depression
- MeSH terms
- Adult, Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, N-Methylaspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Diagnostic and Statistical Manual of Mental Disorders, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.